-+ 0.00%
-+ 0.00%
-+ 0.00%

NeOnc says Abu Dhabi health regulator grants IND status for NEO100 glioma trials

PUBT·06/23/2026 13:01:13
Listen to the news
NeOnc says Abu Dhabi health regulator grants IND status for NEO100 glioma trials
  • NeOnc Technologies won UAE IND clearance from Abu Dhabi’s Department of Health for NEO100 in recurrent Grade III-IV gliomas.
  • Authorization supports adult trials through Phase 2, with a pediatric pathway under further protocol review.
  • Top-line data from the fully enrolled NEO100-01 Phase 2a study are expected by end-July 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230900PRIMZONEFULLFEED9750875) on June 23, 2026, and is solely responsible for the information contained therein.